Nicox S.A. Acquires Aciex Therapeutics, Inc.

Viatris Acquires Aculys Pharma to Secure CNS Assets and Japan/APAC Rights

October 15, 2025

Pharmaceuticals

Viatris Inc. has acquired clinical-stage Aculys Pharma, Inc., obtaining exclusive development and commercialization rights in Japan for pitolisant and rights in Japan and select Asia‑Pacific markets for Spydia (diazepam) nasal spray. The deal includes an upfront payment to Aculys shareholders with additional milestone and royalty payments, and is intended to strengthen Viatris' presence and CNS capabilities in Japan.

ABIONYX Pharma Acquires IRIS Pharma via Contribution in Kind

December 6, 2021

Biotechnology

ABIONYX Pharma completed a contribution in kind of 100% of the capital of IRIS Pharma Holding, issuing new ABIONYX shares at €3.60 per share to acquire the business. IRIS Pharma will become a subsidiary of ABIONYX while remaining operationally independent as a specialist CRO in ophthalmology, providing ABIONYX with ophthalmology R&D capabilities and a potential portfolio of biologic candidates.

Ionis Pharmaceuticals to Acquire Remaining Stake in Akcea Therapeutics

August 31, 2020

Biotechnology

Ionis Pharmaceuticals agreed to acquire the approximately 24% of Akcea Therapeutics it does not already own for $18.15 per share in cash, implying a fully diluted transaction value of about $500 million. The deal will be executed via a tender offer followed by a second-step merger, and Ionis expects to complete the transaction in Q4 2020 to consolidate Akcea's pipeline, commercial products and cash while realizing cost synergies.

Sorrento Therapeutics Acquires ACEA Therapeutics

June 1, 2021

Biotechnology

Sorrento Therapeutics completed the acquisition of ACEA Therapeutics, making ACEA a wholly owned subsidiary and issuing Sorrento common stock plus contingent milestone and royalty payments. The deal adds multiple clinical- and preclinical-stage new chemical entities (including abivertinib) to Sorrento's oncology and immunotherapy pipeline and expands its development and manufacturing footprint in China and North America.

AmerisourceBergen Acquires PharmaLex from AUCTUS in €1.28bn Transaction

December 31, 2022

Healthcare Services

AmerisourceBergen Corporation acquired a majority stake in PharmaLex from funds advised by AUCTUS Capital Partners AG in a transaction that closed at year-end 2022 for approximately EUR 1.28 billion. PharmaLex, a Germany-headquartered provider of regulatory, clinical development and pharmacovigilance services to the life sciences industry, was grown under AUCTUS through a buy-and-build program of 38 add-ons and will expand AmerisourceBergen's global pharmaceutical solutions.

Azelis Acquires Azienda Chimica e Farmaceutica (ACEF)

July 9, 2025

Industrial Services

Azelis Group NV has acquired 100% of Azienda Chimica e Farmaceutica (ACEF), a Piacenza-based distributor of specialty raw materials and ingredients for the cosmetic, nutraceutical, galenic and pharmaceutical markets. The acquisition strengthens Azelis's footprint in Italy, expands its product portfolio and technical capabilities, and brings ACEF's laboratories and GMP-compliant facilities into Azelis's network.